ASKA Pharmaceutical Holdings Holds Successful Shareholders Meeting; Rejects Two Proposals

TOKYO, Jun 25 (Pulse News Wire) – Aska Pharmaceutical Holdings CO.,LTD. (4886.T) reported the results of its fifth regular shareholders meeting held on June 24, 2026.

All eleven proposals made by the company were approved, except for the shareholder proposal to appoint two non-audit committee directors, which was rejected. The meeting saw high approval rates across various resolutions, such as the distribution of surplus funds, amendments to the articles of incorporation, and the appointment of ten directors excluding audit committee members. Notably, the resolution concerning large-scale tender offers initiated by Dalton and others received significant support, with 87.31% voting in favor.

Directors including Yoshioka Soichi, Maruo Atsunori, and others were elected with strong backing, while the proposal to appoint James B. Rosenwald III and Hayashi Shiro as non-audit committee directors garnered only 22.06% and 22.07% support respectively. The company thanked shareholders for their continued support and emphasized its commitment to sustainable growth and long-term value enhancement under the newly appointed management team.